Figure 3From: High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohortGating strategy for expression of NKp46 and NKG2D by CD56 + dimNK cells: Panel A shows NKp46 APC FMO, B shows CD56dimexpressing NKG2D (CD56+CD16+/-NKG2D+); C shows NKG2D PE FMO and D shows CD56dimexpressing NKG2D (CD56+CD16+/-NKG2D+).Back to article page